Kierah Bircham – Cycle Pharmaceuticals

Skip to content

Search for:

About us
PRODUCTS
- REPORTING AN ADVERSE EVENT
PIPELINE
- TECHNOLOGY PARTNERSHIPS
- COMMERCIAL PARTNERSHIPS
Patients
- PATIENT ADVOCACY
- COMPASSIONATE USE
NEWS
CAREERS

Home/Kierah Bircham

About Kierah Bircham

This author has not yet filled in any details.
So far Kierah Bircham has created 0 blog entries.

Search for:

Recent Comments

Recent Posts

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer
Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors
NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand
Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department
Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

Archives

May 2021
April 2021
March 2021
December 2020
October 2020
September 2020
August 2020
May 2020
April 2020
March 2020
December 2019
November 2019
October 2019
April 2019
November 2018
August 2018
November 2017
August 2017
June 2017
December 2016
November 2016

Categories

Corporate
Generics
News
Nityr
Resource

Meta

Log in
Entries feed
Comments feed
WordPress.org

Popular
Recent
Comments

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1
August 1st, 2017
Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)
August 5th, 2020
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology
May 5th, 2020

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer
May 25th, 2021
Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors
April 29th, 2021
NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand
March 15th, 2021

No comments have been published yet.

Categories

Corporate
Generics
News
Nityr
Resource

Find us on Facebook

Archives

May 2021
April 2021
March 2021
December 2020
October 2020
September 2020
August 2020
May 2020
April 2020
March 2020
December 2019
November 2019
October 2019
April 2019
November 2018
August 2018
November 2017
August 2017
June 2017
December 2016
November 2016

Search for:

Recent Posts

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer
Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors
NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand
Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department
Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

Recent Tweets

A well-designed search result page that is informative & useful goes a long way in delivering successful interactio… twitter.com/i/web/status/1…
6 hours ago
A detailed look at building a sleek #WooCommerce shop checkout process with the #avada #WebsiteBuilder - Streamline… twitter.com/i/web/status/1…
1 day ago
Each purchase of #avada bit.ly/2wJxHQu includes 6 months of free hands-on support. When you register the p… twitter.com/i/web/status/1…
2 days ago

Categories

Corporate
Generics
News
Nityr
Resource

Legal Policies
REPORTING AN ADVERSE EVENT
Contact

CYCLE Pharmaceuticals Limited is registered in England and Wales. Registration number 07933058.

GL-0043 (Date of Preparation: September 2020)

UK: +44 1223 354118
US: +1 800 903 1793
info@cyclepharma.com